VAD-t (vincristine, adriamycin, dexamethasone and low-dose thalidomide) is an effective initial therapy with high response rates for patients with treatment naive multiple myeloma (MM) [abstract 3463] - Chanan-Khan, AA; Miller, KC; McCarthy, P (Blood, 2004)
et al.